Saturna Capital Corp Acquires 15,286 Shares of Boston Scientific Corporation $BSX

Saturna Capital Corp increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 57.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,791 shares of the medical equipment provider’s stock after purchasing an additional 15,286 shares during the period. Saturna Capital Corp’s holdings in Boston Scientific were worth $4,489,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BSX. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares during the period. Geode Capital Management LLC grew its position in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the period. Invesco Ltd. increased its stake in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after purchasing an additional 834,274 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Amundi increased its position in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after acquiring an additional 311,034 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 175,782 shares of company stock valued at $17,742,314. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $99.23 on Wednesday. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The stock has a market cap of $147.10 billion, a PE ratio of 53.06, a P/E/G ratio of 2.02 and a beta of 0.58. The firm has a 50-day moving average of $99.41 and a 200-day moving average of $102.51. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Truist Financial increased their price objective on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Robert W. Baird upped their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Buy” and an average price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.